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2SUMMARY
Thioredoxins (Trx) are small ubiquitous proteins that participate in different
cellular processes via redox-mediated reactions. We report here the identification and
characterization of a novel member of the thioredoxin family in human, named Sptrx
(sperm-specific trx), the first with a tissue-specific distribution, located exclusively in
spermatozoa. Sptrx ORF encodes for a protein of 486 amino acids comprised of two
clear domains: an N-terminal domain consisting of 23 highly conserved repetitions of a
15-residue motif and a C-terminal domain typical of thioredoxins. Northern analysis
and in situ hybridization shows that Sptrx mRNA is only expressed in human testis,
specifically in round and elongating spermatids. Immunostaining of human testis
sections identified Sptrx protein in spermatids while immunofluorescence and
immunogold electron microscopy analysis demonstrated Sptrx localization in the
cytoplasmic droplet of ejaculated sperm. Sptrx appears to have a multimeric structure
in native conditions and is able to reduce insulin disulfide bonds in the presence of
NADPH and thioredoxin reductase. During mammalian spermiogenesis in testis
seminiferous tubules and later maturation in epididymis, extensive reorganization of
disulfide bonds is required to stabilize cytoskeletal sperm structures. However, the
molecular mechanisms that control these processes are not known. The identification of
Sptrx with an expression pattern restricted to the post meiotic phase of
spermatogenesis, when sperm tail is organized, suggests that Sptrx might be an
important factor in regulating critical steps of human spermiogenesis.
3INTRODUCTION
Thioredoxins (Trx) are low-molecular weight proteins (12 kDa) that catalyze thiol-
disulfide redox reactions by the reversible oxidation of the cysteine residues of their
conserved active site WCGPC (1). Thioredoxins are maintained in their active reduced
form by the flavoenzyme thioredoxin reductase (TrxR) that uses the reducing power of
NADPH, which constitutes the so-called thioredoxin system (2). All the organisms from
bacteria to human appear to have at least one complete thioredoxin system and the
progressive complexity of eukaryotic organisms is also reflected in the increasing
number of thioredoxin systems. Thus, E. coli contains two thioredoxins and one
thioredoxin reductase; yeast has two thioredoxin systems, one in cytosol and the other
one in mitochondria, and photosynthetic organisms have several thioredoxin systems in
different cellular compartments including chloroplasts. Finally, mammalian cells have,
at least, two thioredoxin systems located in the cytosol and mitochondria, respectively
(3). Different functions have been assigned to thioredoxins relying mostly on their
general disulfide-reductase activity. In mammals, cytosolic Trx has been shown to be an
antioxidant, a modulator of apoptosis, cell growth and differentiation and also a
regulator of the DNA-binding activity of several transcription factors (following
translocation into the nucleus), while the function of the mitochondrial thioredoxin
system has not been yet elucidated although it is thought to constitute a major
antioxidant defense mechanism. A common characteristic of both mammalian systems
is their ubiquitous presence in all the tissues investigated within the same organism
(3,4).
The human spermatozoon provides the male pronucleus for fertilization and to
achieve this objective it has developed a highly specialized morphology organized into
two major structures: the head and the tail or flagellum (5). The head contains the
4highly condensed DNA contributed by the male and all the cellular components that
ensure egg recognition and sperm-egg fusion while the flagellum is responsible for
sperm motility and energy production for the propulsive apparatus (6,7). Mammalian
sperm tail is divided into three main regions running in a proximal to distal direction
away from the sperm head: the mid-piece (that is attached to the sperm head by the
neck or connecting piece), the principal piece and the end piece (for a scheme on sperm
tail organization see (7) and (8)). The flagellum of the mammalian spermatozoa is
organized around the central axoneme which consists of 9+2 microtubules, similar to
that seen in the cilia and flagella of all eukaryotic cells and extends through the full
length of the flagellum (7). In addition, mammalian spermatozoa contain characteristic
cytoskeletal elements associated with the axoneme, namely outer dense fibers (ODF)
and fibrous sheath (FS), that do not have any counterparts in any other cell type (5).
ODF are adjacent to the axoneme and extend from the neck to the posterior end of the
principal piece. In the middle piece, nine ODF (each one associated with one axonemal
microtubule doublet) are surrounded by a helically wrapped mitochondrial sheath, that
supplies the energy required for motility. This distribution pattern changes in the
principal piece where FS replaces the mitochondrial sheath and the ODF number is
reduced from nine to seven that progressively decrease in size. FS is composed of two
longitudinal columns, running opposite to doublets 3 and 8 in replacement of the two
missing ODF, connected by a series of ribs formed of closely packed filaments (5). The
function of ODF and FS is not fully elucidated but it seems to be related with the control
of the flagellar motion (8) and protection against shearing forces during epididymal
transit (9). In recent years, the number of sperm-specific proteins has increased
considerably although it is estimated that only 10-20% of the sperm polypeptides have
been identified. The present work adds a new member to the list of sperm-specific
proteins, the first belonging to the thioredoxin family.
5EXPERIMENTAL PROCEDURES
cDNA cloning of human Sptrx gene. The Basic Local Alignment Search Tool
(BLAST) (10) was used to identify human EST clone-encoded proteins similar to the
ORF of human Trx1 or Trx2 (11,12). One of these EST entries (AA431210) was found to
encode a putative novel human thioredoxin like protein. Based on this sequence, the
nested primers hSptrx-R1/hSptrx-R2 (nucleotides 1653-1627 and 1605-1579, all
nucleotide numbers referred to GenBank entry AF080095) and hSptrx-F4/hSptrx-F5
(nucleotides 1297-1320 and 1335-1359, respectively) were used for 5´- and 3´-RACE in a
human testis cDNA library (Clontech) to isolate human Sptrx cDNA. The resulting
sequences were used to amplify by PCR the full-length cDNA from the same library.
Northern blot analysis: Human multiple tissue Northern blots and human RNA
Master blot with poly(A)+ RNA from different tissues were purchased from Clontech.
The human Sptrx ORF was labeled with [a-32P]dCTP (Rediprime random primer
labeling kit, Amersham) and hybridized at 65°C overnight in ExpressHyb Solution
following the protocol provided by Clontech. The blots were also hybridized with
human GAPDH as control. The blots were scanned and quantified with the Gel Pro
Analyzer program (Media Cybernetics).
Expression and purification of human Sptrx. The ORF encoding human Sptrx
was cloned into the BamHI-EcoRI sites of the pGEX-4T-1 expression vector (Pharmacia)
and transformed in E. coli BL21(DE3). The induction of the fusion protein was
performed as previously described (13). Overexpressing cells were disrupted by 10 min
sonication and the supernatant was cleared by centrifugation at 15,000 x g for 30 min
and loaded onto a glutathione sepharose 4B column (Pharmacia Biotech). Binding to the
6matrix was allowed to occur during 2 h at room temperature. Thrombin (5U per mg
fusion protein) was used to remove GST by incubation overnight at 4°C. The resulting
protein preparation was then subjected to ion exchange chromatography using a
HiTrap Q column (Pharmacia Biotech) and human Sptrx was eluted using a gradient of
NaCl. Protein concentration was determined from the absorbance at 280 nm assuming a
molar extinction coefficient of 7690 M-1 cm-1 that was calculated using the Protean
Program included in the DNASTAR Software Package (DNASTAR Inc., Madison,
USA). The cloning, overexpression and purification of the truncated form of human
Sptrx (h D Sptrx) was identical to that described for the full-length protein except that the
ion exchange purification step was not required as the protein eluted in a pure form
following thrombin cleavage.
Enzymatic activity assays. Two different enzymatic assays were used to
determine the ability of human Sptrx to reduce insulin in vitro. In the so-called DTT
assay, DTT is used as reductant and the assay was carried out as previously described
(11). The other assay used thioredoxin reductase and NADPH as electron donors for
thioredoxin and was performed essentially as described elsewhere (13). In both cases
human Trx1 was used as control.
Antibody production and immunoblotting analysis. Purified GST-hSptrx was
used to immunize rabbits (Zeneca Research Biochemicals). After six immunizations,
serum from rabbits was purified by ammonium sulfate precipitation. Affinity purified
antibodies were prepared using a cyanogen bromide-activated Sepharose 4B column,
onto which 0.5 mg recombinant N-terminal Sptrx fragment (lacking the thioredoxin
domain) had been coupled using the procedure recommended by the manufacturer
(Pharmacia). Specificity of the antibodies was tested by western blotting using
7recombinant hSptrx and total cell extracts. Immunodetection was performed with
horseradish peroxidase-conjugated donkey anti-rabbit IgG diluted 1:5000 following the
ECL protocol (Amersham Corp.).
Preparation of spermatozoa and extraction of sperm proteins. Semen samples
from healthy donors were allowed to liquefy at room temperature and separated from
seminal plasma by centrifugation (1000 x g) for 10 min at room temperature. After two
washes in PBS the pelleted spermatozoa were frozen at -20°C until use. The sperm
pellet was solubilized in a lysis buffer containing Tris-HCl 0.1 M pH 8.0, NaCl 0.15 M,
protease inhibitor cocktail (Boehringer Mannheim) and phosphatase inhibitor cocktail
(SIGMA) at the concentration recommended by the manufacturers. Samples were then
subjected to three cycles of freezing/thawing in dry ice-ethanol, incubated for 30 min
on ice and centrifuged at 14000 rpm for 30 min. The soluble fraction was used for
further analysis.
In situ hybridization, immunocytochemistry and immunoelectron
microscopy. For in situ hybridization, human testes were obtained from
orchiectomies performed due to prostate cancers. The samples were frozen on dry
ice, sectioned with Microm HM 500 cryostat at 14 m and thaw-mounted onto
polylysine glass slides. The sections were stored at –20C until use. Four
oligonucleotide probes (nucleotides 181-220, 957-996, 1208-1257 and 1519-1558 of
human Sptrx cDNA) were used. All probes produced similar results when used
separately and were usually used simultaneously to intensify the signal. Several
control probes with the same length and similar GC content and specific activity
were used to determine the specificity of the hybridization. In situ hybridization
was carried out as described previously (14).
8For immunocytochemistry, paraffin sections containing multiple human
tissues (T1065, Lot: 9994A) were obtained from Dako (Copenhagen). In addition
routine paraffin sections of human testis were used. For immunofluorescence
analysis human sperm samples were obtained from healthy volunteers.
Immunocytochemistry was performed as described previously (15) either by the
ABC-method or by indirect immunofluorescence method using goat anti-rabbit-
FITC (1:100, 30 min, Boehringer-Mannhein) as a secondary antibody . The
fluorescence samples were embedded in PBS-glycerol mixture containing 0.1% p-
phenylenediamine. The sections were examined with Nikon Microphot-FXA
microscope equipped with proper fluorescent filters. For electron microscopy
immunocytochemistry, see procedures previously described (5,16). Affinity
purified anti Sptrx antibodies were used at 1/20 dilution and colloidal gold-
conjugated goat anti-rabbit IgG at 1/20 dilution was the secondary antibody.
9RESULTS
cDNA cloning and expression, sequence analysis, genomic organization and
chromosomal localization of human Sptrx gene. By sequence comparison we found
that Genbank EST entry AA431210 encoded a putative novel human thioredoxin
sequence. Based on this sequence, we designed specific primers and performed 5’- and
3’-RACE PCR analysis in a human testis cDNA library to clone the full-length cDNA
sequence of this novel protein. The complete sequence of the cDNA consists of an ORF
of 1461 bp, a 5’-UTR of 180 bp including three stop codons in frame and a very short 3’-
UTR of 17 bp before the poly(A)+ tail (Fig. 1). Human Sptrx ORF encodes a protein of
486 amino acids with an estimated molecular mass of 53.3 kDa and a pI of 4.82. Despite
another methionine residue located seven positions downstream, we have chosen the
first methionine as translation start point since it is located in a better Kozak-context for
initiation of translation (17). Analysis of human Sptrx sequence identified two distinct
domains: a N-terminal domain (comprising the first 375 residues) displaying only a
very weak similarity with wheat proline-rich protein (18) and mouse neurofilament H
protein (19), and a C-terminal domain (comprising the last 111 residues) similar to the
previously described Trx1 and Trx2 (11,12). The N-terminal domain is characterized by
a unique arrangement of residues organized as 23 repeats of a 15-residue motif shortly
after the start methionine. As shown in Figure 1, this motif has a general pattern
(QPK(X)GDIPKS(P/S)E(K/E)(X)I) which is very conserved among the different
repetitions and very rich in both basic (Lys) and acidic residues (Glu, Asp) that are
responsible for the low pI of 4.82 and a net charge at pH 7.0 of –26.32. Regarding the C-
terminal thioredoxin domain, many of the structural amino acids that are conserved in
mammalian thioredoxins like Phe-11, Asp-26, Ala-29, Pro-40, Asp-58 or Lys-81
(numbers referred to those of human Trx1) are also conserved in Sptrx (Fig. 2). The
10
major characteristic of the C-terminal thioredoxin domain of Sptrx is the presence of
four additional cysteines besides the two at the active site (Fig. 1). More strikingly, the
three additional cysteine residues in human Trx1 (positions 62, 69 and 74) are conserved
in human Sptrx (residues 443, 450 and 454 respectively) while the fourth Sptrx cysteine
residue, at position 471, corresponds to Ser-90 in Trx1 (Fig. 2) (20). Comparison of the
protein sequence with PROSITE database (21) identified, along with the above
mentioned thioredoxin domain, several potential phosphorylation sites for protein
kinases CKI, CKII, GSK3, p34cdc2 and PKC and two highly scored PEST sequences for
proteasome-dependent degradation centered at positions 16 and 375, respectively (Fig.
1). In addition, the protein sequence does not reveal any signal peptide to target the
protein to any subcellular compartment. This is further confirmed by the expression of
a fusion protein of human Sptrx and GFP at its C-terminus resulting in a cytosolic
localization (data not shown). Sptrx mRNA 3´-UTR is composed of only 17 nucleotides
and inspection of the sequence immediately upstream from the stop codon identifies a
putative non-canonical poly(A)+ signal (ATTAAA) that might indeed drive
polyadenylation (22).
Multiple-tissue Northern blots were used to determine the size and tissue
distribution of human Sptrx mRNAs using the ORF as the probe. Human Sptrx mRNA
was detected only in human testis as a single band of 1.7 kb in good agreement with the
size of the cloned cDNA (Fig. 3A). No signal was obtained in any other tissue after
longer exposure. To evaluate the possibility that Sptrx mRNA could be expressed in
other tissues not present in these blots, we also screened an RNA dot blot containing
poly(A)+ RNAs from 50 different human tissues. Among the tissues examined,
hybridization signal was observed only in testis mRNA (Fig. 3B).
A homology search in GenBank identified Sptrx genomic region in the genomic
BAC clone AC006238. The main feature of human Sptrx gene is the lack of introns
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within the coding region and the presence of only one intron of 508 bp in the 5´-UTR
(Fig. 4). This intron, that interrupts the first in-frame 5´-UTR stop codon (Fig. 1),
displays all the typical intron features as it conforms to the GT/AG rule and contains
the splicing branch point consensus TGCTAAT and the downstream pyrimidine tract
(Fig. 4). Finally, the BAC clone AC006238 has been mapped to human chromosome
18p11.2-11.31, between the markers D18S459 and D18S482, by PCR screening of a
human-rodent radiation panel (Fig. 4). To our knowledge, no male germ cell deficiency
or any other type of reproductive anomaly has been reported to map in this region.
Expression of recombinant human Sptrx and enzymatic activity. Recombinant
human Sptrx migrated in SDS-PAGE at 91 kDa size (Fig. 5A) while its theoretical size is
53 kDa. This retardation in the migration of the protein could be explained by its low pI
and net negative charge at neutral pH. In addition, computer analysis of the Sptrx
sequence predicts that the N-terminal domain of the protein is organized in a -helical
secondary structure which might also contribute to this anomalous migration as
described for other testis proteins (23,24). Next, we performed PAGE under non-
denaturing conditions and human Sptrx migrated at approximately 180 kDa thus
suggesting that it might be multimeric in its native state (Fig. 5B). Preincubation of the
protein with DTT did not modify this pattern of migration implying that the multimeric
conformation is maintained by non-covalent forces.
Enzymatic activity of thioredoxins is usually assayed by their capacity to reduce
the disulfide bonds of insulin using either DTT as artificial reductant or NADPH and
thioredoxin reductase as a more physiological reducing system (2). Figure 6A shows the
activity of human recombinant Sptrx with DTT as reducing agent. Surprisingly, the
truncated form of Sptrx expressing only the thioredoxin domain did not display a
significant activity over the background, suggesting that the active site is buried in this
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truncated form and only accessible in the full-length form. In another assay where
NADPH and calf thymus thioredoxin reductase are used as electron donors for Sptrx,
both the full-length and the truncated form are active. Similarly, the truncated form of
Sptrx is also less active than the full-length protein indicating that the accessibility of
the active site is maintained, at least in part, by the N-terminal domain of Sptrx.
However, the enzymatic activity is higher in the oxidized forms than in the reduced
ones in contrast with Trx1 used as control (Fig. 6B).
Tissue expression, cellular and subcellular localization of human Sptrx. To
investigate the expression pattern of Sptrx mRNA, in situ hybridization was performed
in human testis sections and showed that it is expressed in round and elongating
spermatids with no signal in the rest of the testicular cells (Fig. 7). Similar results have
been obtained in mouse testis sections (M. Pelto-Huikko and A Miranda-Vizuete,
unpublished results). Affinity purified antibodies were used to study the expression
pattern of Sptrx protein in different human tissues and cell lines. As shown in Figure
8A, only human testis and sperm cell extracts expressed Sptrx as a band of approx. 91
kDa in agreement with the migration of the recombinant protein in SDS gels. No signal
was detected in any other tissue or cell line used as control. We also studied the
expression of Sptrx in a blot of different human testis and prostate tumours and found
no difference with respect to normal tissues (data not shown). Next, we used these
antibodies to investigate whether we could identify Sptrx homologues in testis extracts
from other mammals. Figure 8B shows that they recognize a similar band in mouse, rat
and bovine testis extracts.
The unforeseen result of the sperm-specific localization of human Sptrx prompted
us to investigate whether other members of the two thioredoxin systems (cytosolic and
mitochondrial) (3,25) as well as a newly identified thioredoxin reductase highly
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expressed in testis (26) are present in these cells. We used specific antibodies against all
these proteins and by Western blot analysis we were able to identify all of them in both
human testis and sperm extracts (Fig. 8C). To address the question whether Sptrx
protein distribution paralleled the mRNA expression, we performed
immunohistochemical analysis in human testicular sections that revealed that Sptrx
expression was restricted to spermiogenesis and most prominently expressed in round
and elongating spermatids. Other cellular types like spermatogonia, primary
spermatocytes, Leydig and Sertoli cells were not stained (Fig. 8D). Identical Sptrx
distribution pattern has been observed in rat and mouse testis (R. Oko, M. Pelto-Huikko
and A. Miranda-Vizuete, unpublished results). Immunofluorescence of human
ejaculated spermatozoa showed that Sptrx was localized from the caudal region of the
head to the end of the principal piece (Fig 8E). However, when using Triton during the
fixation protocol this signal was removed thus suggesting that Sptrx is contained (loose)
within the tail cytoplasm and the cytoplasmic droplet. To further confirm this point, we
performed immunogold electron microscopy analysis in human ejaculated spermatozoa
and found that Sptrx is distributed mostly in the cytoplasmic droplet although some
scattering of residual labeling was present throughout the sperm tail (Fig 8F-G). These
results in human ejaculated sperm have been also validated for rat, mouse and bull
sperm (R. Oko and A. Miranda-Vizuete, unpublished results).
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DISCUSSION
During the last five years an increasing number of genes which expression is
restricted to spermatogenesis have been reported and the fact that most of their
encoded proteins display enzymatic or regulatory properties suggests that they might
play a more active role in sperm function than merely structural. In this context, we
report here the cloning and characterization of Sptrx, a novel member of the thioredoxin
family exclusively expressed in human spermatozoa representing the first mammalian
member of the thioredoxin family with a tissue-specific distribution.
Sptrx cDNA was cloned from a human testis cDNA library and both ORF and
UTRs display important features. Analysis of Sptrx ORF identifies a two-domain
structure consisting of a N-terminal part organized in 23 repeats of 15 amino acid
residues with no homology to any other protein in the databases and a C-terminal
domain similar to thioredoxin. Sptrx N-terminus is rich in charged residues and several
putative sites for phosphorylation by different kinases can be identified. Among these
sites, PKC and casein kinase II appear to be the most likely sites of phosphorylation
sites in serine residues. Phosphorylation is one of the major regulatory mechanisms in
sperm physiology and practically all the different cellular processes that sperm
undergoes e. g.  acrosome reaction, capacitation, hyperactivation, motility or binding to
egg zona pellucida are mediated by this mechanism (7). In addition, a complete set of
different kinases has been identified in mammalian sperm cells both ubiquitous and
sperm-specific (27). Another important feature of the N-terminal domain of Sptrx is the
presence of two PEST sequences, which have been reported to be involved in rapid
degradation of proteins by the ubiquitin 26S proteasome machinery (28). Ubiquitin-
dependent degradation has recently been put forward as an important general
mechanism for selective degradation of defective sperm along with other contaminants
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of cellular origin, during epididymal transit (29). Preliminary experiments show that
Sptrx is phosphorylated by PKC and ubiquitinated in vitro (A. Miranda-Vizuete,
unpublished results).
The Sptrx gene is organized in two exons separated by one intron located in the 5´-
UTR that might be involved in Sptrx regulation as it has been described for other testis-
specific proteins (30). On the other hand, the 3´-UTR is unexpectedly short with only 17
nucleotides and lacking polyadenylation signal, although inspection of the ORF
sequence immediately upstream from the stop codon identifies a putative non-
canonical poly(A)+ signal (ATTAAA). To our knowledge, there are only two cases
where a polyadenylation signal is located within the ORF of the corresponding gene
(31,32). Although further experiments are required to confirm this point, the distance of
20 nucleotides between the polyadenylation signal to the poly(A)+ site and a GU-rich
element 30 nucleotides downstream from the poly(A)+ site supports this possibility (22).
Taken together, Sptrx gene organization reveals an unusual case within thioredoxin
family. While other members like Trx1 or Trx2 are composed of five and three exons,
respectively (33 and A. E. Damdimopoulos, unpublished results) neither the Sptrx
genomic segment corresponding to the thioredoxin domain nor the N-terminal
repetitive domain are interrupted by any intron. It is then reasonable to speculate that
the Sptrx thioredoxin domain might have arisen as a retroposition event from the
mature original mRNA ancestor and integrated randomly in the genome (34). Whether
the N-terminal domain was already at the integration locus as a pre-existing gene or
was acquired after the thioredoxin domain integration can not be inferred as no
homologue has been yet identified. Most of the expressed intronless retroposons,
including Sptrx, are testis specific forms. This apparent tissue-specificity may be due to
transcriptional promiscuity in testes as the retroposition event is required to occur in
the germ line to be fixed in the population (35).
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Sptrx migrates at 180 kDa under non-reducing conditions suggesting a multimeric
native conformation. When assayed with calf thymus thioredoxin reductase it can
reduce insulin disulfide bridges but this activity is higher in the oxidized form than in
the reduced one. This is the first report where a thioredoxin has higher activity in its
oxidized form. As noted previously, Sptrx contains four additional cysteine residues
that might form intra- or inter-monomeric disulfide bonds therefore stabilizing the
protein. Although Sptrx native conformation is not maintained by disulfide bonds as
shown by non-denaturing gel assay, the decrease of the enzymatic activity after
preincubation with a reducing agent indicates that additional cysteine residues in Sptrx
modulate its activity. A truncated form of Sptrx lacking the N-terminal domain only
displays residual activity implying that the N-terminus is necessary to maintain the
accessibility of the active site.
The synthesis of the sperm cytoskeletal polypeptides has been shown to occur in
the cytoplasm of elongating spermatids, which is consistent with the expression pattern
obtained for Sptrx and corresponds to the growth of the structures that will organize
the sperm tail. We have found that all the thioredoxins and thioredoxin reductases so
far identified are present in human ejaculated sperm. Thus, although the specific
function that they play in spermatozoa is not known, their presence in the mature cell
suggests an important role in sperm physiology. Particularly interesting is the presence
in sperm of a novel form of thioredoxin reductase that has been found to be highly
expressed in testis (26). This novel TrxR together with Sptrx might constitute the first
tissue-specific thioredoxin system, although colocalization of both proteins has not been
addressed.
Disulfide bond formation is a very important issue in sperm physiology. The
nuclear and accessory structures of mammalian sperm tail become stabilized by
extensive disulfide bonding during spermiogenesis and epididymal maturation and
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this stabilization is reversed during fertilization by the reduction of these disulfide
bonds (36,37). As we have demonstrated, Sptrx is able to function as a reductant in vitro
and displays a spatial and temporal expression in the tail of elongating spermatids
which occurs simultaneously with the assembly of ODF and FS. Our data suggests that
Sptrx could indeed participate in the regulation of this assembly process by reducing
non-correct disulfide pairings thus favouring the generation of the correct disulfide
bonds between the different sperm tail constitutents.
In an attempt to identify possible functions of Sptrx in sperm physiology we
studied the involvement of Sptrx in the formation of the sperm capsule, a structure that
embeds the helix of mitochondria in the middle piece of sperm tail. PHGPx protein
represents at least 50% of the capsule material and it is found in an enzymatically
inactive, oxidatively cross-linked, unsoluble form (38). The switch of PHGPx from a
soluble active enzyme to an enzymatically inactive structural protein has been shown to
occur during differentiation of spermatids into spermatozoa (once the mitochondria
have been helically arranged around the axoneme and ODF in the sperm tail middle
piece) and to be dependent on thiol groups in proteins distinct from PHGPx (38).
Despite Sptrx meeting these two criteria, it is not involved in the process as neither the
recombinant protein could oxidize soluble PHGPx nor the Sptrx antibodies could
prevent aggregation in the presence of hydrogen peroxide (L. Flohé, personal
communication).
In conclusion, the identification of Sptrx in human spermatozoa opens up a new
dimension within the thioredoxin field. Its expression during sperm tail formation
strongly indicates an important role in this process and therefore a potential target for
male factor infertility studies. There are numerous reports describing sperm flagellum
pathologies for which the molecular bases in unknown. Among those, the best
characterized is dysplasia of the fibrous sheath (DFS), a human sperm defect resulting
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in male sterility that consists of a complete disorganization of this structure which is
already evident in spermatids by the loose arrangement of the FS ribs dispersed in the
cytoplasmic matrix (39). The simultaneous expression of Sptrx at the time that FS
assembles suggests that there might be a correlation between an anomalous expression
of Sptrx and the development of DFS. If so, diagnosis of patients affected with DFS or
any other sperm tail pathology might be helped by screening of Sptrx status.
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LEGENDS TO THE FIGURES
Fig. 1. Nucleotide and amino acid sequence of human Sptrx. The nucleotide
numbers are displayed on the right and the amino acid numbers on the left. The three
stop codons in frame within the 5´-UTR are underlined. The up arrow indicates the 5´-
UTR intron site while the down arrow indicates the thioredoxin domain start. The two
putative sites for ubiquitination are double underlined. The conserved thioredoxin
active site and the four additional cysteine residues are boxed.
Fig. 2. Alignment of the predicted amino acid sequence of Sptrx thioredoxin
domain with human Trx1 (11) and the mature form of human Trx2 (12). Identical
residues are displayed in black boxes. The arrows indicate the position of the four
additional cysteines in Sptrx and the active site is boxed.
Fig. 3. Expression pattern of human Sptrx mRNA. (A) Human multiple tissue
northern blot. The human Sptrx probe hybridized with one mRNA species at 1.7 kb
only in testis. (B) Human RNA master blot. The human Sptrx probe hybridized with
testis mRNA (arrow). For a complete list of tissues see Clontech catalogue
(www.clontech.com). In both cases GADPH was used as control to determine the
relative amount of mRNA from each tissue. P.B.L., peripheral blood leukocytes.
Fig. 4. Genomic organization and chromosomal localization of human Sptrx
gene. The sequence of the 5´-UTR intron is shown, the conserved GT/AT dinucleotides
at the intron junction are in bold and the splicing branch point is boxed. Human Sptrx
gene is located at 24.3-32.4 cM from the top of the linkage group of human chromosome
24
18. By comparing this location with other genes in the region we have mapped it to
18p11.2-11.31.
Fig. 5. Expression and purification of human recombinant Sptrx protein. (A)
SDS-PAGE analysis. After IPTG induction human Sptrx was purified as GST fusion
protein and thrombin cleavaged with 5 U/mg protein (Lane 1) and after ion exchange
column (Lane 2). 5 m g of protein were loaded onto a 10% gel. (B) Native-PAGE analysis
of human recombinant Sptrx protein. 2 m g of purified Sptrx were loaded in a 4-15%
gradient phast system gel (Pharmacia-Biotech).
Fig. 6. Enzymatic activity of human Sptrx. Purified Sptrx was assayed for its
ability to reduce insulin disulfide bonds. (A) DTT was used as electron donor: (O) Trx1,
(q) Sptrx, (D) Truncated Sptrx, (  ) DTT alone. Proteins were used at a final
concentration of 5 m M and the reaction was initiated adding 1 m l of 100 mM DTT. (B)
NADPH and thioredoxin reductase were used as electron donors: (O) Trx1 reduced, (l)
Trx1 oxidized, (q) Sptrx reduced, (n) Sptrx oxidized, (D) Truncated Sptrx reduced, (s)
Truncated Sptrx oxidized. Reduced proteins were obtained by DTT buffer
preincubation (13). The reaction was initiated adding 5 m l of calf thymus thioredoxin
reductase (50A412 unit) and stopped after 20 min by the addition of 6 M guanidine HCl,
1 mM DTNB. All experiments were repeated three times and a representative
experiment is shown.
Fig. 7. In situ hybridization analysis of human Sptrx mRNA distribution.
Dipped sections of human testis were hybridized with Sptrx probe. Grains
demonstrating Sptrx mRNA can be seen over round and elongating spermatids (black
arrowheads). Sertoli cells, pachytene spermatocytes (white arrowheads) and other
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spermatogenic cells at earlier stages of differentiation and interstitial Leydig cells (white
arrows) lack Sptrx mRNA. Bar represents 30 m m.
Fig. 8. Tissue, cellular and subcellular distribution of human Sptrx protein. (A)
Sptrx expression in different human tissues and cell lines. Lanes 1) MCF7, 2) HEK293, 3)
Jurkat, 4) Testis, 5) Prostate, 6) Sperm, 7) Liver. All extracts were at 10 m g except testis 1
m g and sperm 0.1 m g. (B) Interspecies cross-reactivity of human Sptrx antibodies in testis
extracts from different mammalian samples. (Hu) human 1 m g, (Mo) mouse 10 m g, (Bo)
bovine 10 m g and (Ra) rat 10 m g. (C) Identification of all known thioredoxin and
thioredoxin reductases in human sperm. Recombinant TrxR3 is not available and
human liver extract was used as control. Trx2 and TrxR2 are used as His-tagged protein
explaining the slightly higher size. (Re) Recombinant 5 ng, (Li) Liver 10 m g, (Te) Testis
10 m g and (Sp) Sperm 10 m g. (D) Immunocytochemistry of human testis showing strong
Sptrx labeling in the apically localized spermatids, spermatozoa and residual bodies
(arrowheads). Spermatogenic cells at earlier stages of development and Leydig cells are
devoid of staining (arrows). Bar represents 50 m m. (E) Immunofluorescent
demonstration of Sptrx in human ejaculated spermatozoa. Labeling is present from the
postacrosomal region and the neck (arrowhead) through the middle and principal piece
(small arrows). The anterior part of the head is unlabeled (arrow). Bar represents 4 m m.
(F) Electron micrographs of ejaculated sperm middle piece section and (G) tail
longitudinal section showing accumulation of Sptrx labeling throughout the
cytoplasmic droplet (CD) with most of the gold label found outside the saccules (S).
Labeling at much lower incidence, if any, is found randomly distributed in sperm
axoneme (arrowhead). Bars represent 0.2 m m.
CTCAGCACAGGGGAGCCACCTTGAAGCTCTCAAATATCACTGTTG 45
TGAATACAGAGAGGGAAAACCAACTGTAACGTGCCACCCAAATAA 90
AGCTCATTACTAGTCCTGTCCAGCAACGTGCCTCTCCTGGCCCTA 135
GAGTTCTTGGAAATAGCCCAGGCCAAAGAGAAGGCCTTTCTCCCC 180
ATGGTCAGCCACACGTTCCACATGCGCACAGAGGAGTCTGATGCC 225
  M  V  S  H  T  F  H  M  R  T  E  E  S  D  A
TCACAGGAGGGCGATGACCTACCCAAGTCCTCAGCAAACACCAGC 270
  S  Q  E  G  D  D  L  P  K  S  S  A  N  T  S
CATCCCAAGCAGGATGACAGCCCCAAGTCCTCAGAAGAAACCATC 315
  H  P  K  Q  D  D  S  P  K  S  S  E  E  T  I
CAGCCCAAGGAGGGTGACATCCCCAAGGCCCCAGAAGAAACCATC 360
  Q  P  K  E  G  D  I  P  K  A  P  E  E  T  I
CAATCCAAGAAGGAGGACCTCCCCAAGTCCTCAGAAAAAGCCATC 405
  Q  S  K  K  E  D  L  P  K  S  S  E  K  A  I
CAGCCCAAAGAGAGTAACATCCCCAAGTCCTCAGCAAAACCCATC 450
  Q  P  K  E  S  N  I  P  K  S  S  A  K  P  I
CAGCCCAAGCTGGGCAATATTCCCAAGGCCTCAGTGAAGCCCAGC 495
  Q  P  K  L  G  N  I  P  K  A  S  V  K  P  S
CAGCCCAAGGAGGGTGACATCCCCAAGGCCCCAGAAGAAACCATC 540
  Q  P  K  E  G  D  I  P  K  A  P  E  E  T  I
CAATCCAAGAAGGAGGACCTCCCCAAGTCCTCAGAAGAAGCCATC 585
  Q  S  K  K  E  D  L  P  K  S  S  E  E  A  I
CAGCCCAAAGAGGGTGACATCCCCAAGTCCTCAGCAAAACCCATC 630
  Q  P  K  E  G  D  I  P  K  S  S  A  K  P  I
CAGCCCAAGCTGGGCAATATTGCCAAGACCTCAGTGAAGCCCAGC 675
  Q  P  K  L  G  N  I  A  K  T  S  V  K  P  S
CAGCCCAAGGAGAGTGATATCCCCAAGTCCCCAGAAGAAACCATC 720
  Q  P  K  E  S  D  I  P  K  S  P  E  E  T  I
CAGCCCAAGGAGGGTGACATCCCCAAGTCCTCAGCAAAGCCCATC 765
  Q  P  K  E  G  D  I  P  K  S  S  A  K  P  I
CAGCCCAAGCTGGGCAATATTCCCAAGGCCTCAGTGAAGCCCAGC 810
  Q  P  K  L  G  N  I  P  K  A  S  V  K  P  S
CAGCCCAAGGAGGGTGACATCTCCAAGTCCCCAGAAGAAGCCATC 855
  Q  P  K  E  G  D  I  S  K  S  P  E  E  A  I
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CAGCCCAAGGAGGGTGACCTCCCCAAGTCCCTAGAGGAAGCCATC 900
  Q  P  K  E  G  D  L  P  K  S  L  E  E  A  I
CAGCCCAAGGAGGGTGACATCCCCAAGTCCCCAGAAGAAGCCATC 945
  Q  P  K  E  G  D  I  P  K  S  P  E  E  A  I
CAGCCCAAGGAGGGTGACATCCCCAAGTCCCTAGAGGAAGCCATC 990
  Q  P  K  E  G  D  I  P  K  S  L  E  E  A  I
CAGCCTAAGGAGGGTGACATCCCCAAGTCCCCAGAAGAAACCATC 1035
  Q  P  K  E  G  D  I  P  K  S  P  E  E  T  I
CAGCCCAAGAAGGGTGACATCCCCAAGTCCCCAGAAGAAGCCATC 1080
  Q  P  K  K  G  D  I  P  K  S  P  E  E  A  I
CAGCCCAAGGAGGGTGACATTCCCAAGTCTCCAAAACAAGCCATC 1125
  Q  P  K  E  G  D  I  P  K  S  P  K  Q  A  I
CAGCCCAAGGAGGGTGACATTCCCAAGTCCCTAGAGGAAGCCATC 1170
  Q  P  K  E  G  D  I  P  K  S  L  E  E  A  I
CCACCCAAGGAGATTGACATCCCCAAGTCCCCAGAAGAAACCATC 1215
  P  P  K  E  I  D  I  P  K  S  P  E  E  T  I
CAGCCCAAGGAGGATGACAGCCCCAAGTCCCTAGAAGAAGCCACC 1260
  Q  P  K  E  D  D  S  P  K  S  L  E  E  A  T
CCATCCAAGGAGGGTGACATCCTAAAGCCTGAAGAAGAAACAATG 1305
  P  S  K  E  G  D  I  L  K  P  E  E  E  T  M
GAGTTCCCGGAGGGGGACAAGGTGAAAGTGATCCTGAGCAAGGAG 1350
  E  F  P  E  G  D  K  V  K  V  I  L  S  K  E
GACTTTGAGGCATCACTGAAGGAGGCCGGGGAGAGGCTGGTGGCT 1395
  D  F  E  A  S  L  K  E  A  G  E  R  L  V  A
GTGGACTTCTCGGCCACGTGGTGTGGGCCCTGCAGGACCATCAGA 1440
  V  D  F  S  A  T  W  C  G  P  C  R  T  I  R
CCATTCTTCCATGCCCTGTCTGTGAAGCATGAGGATGTGGTGTTC 1485
  P  F  F  H  A  L  S  V  K  H  E  D  V  V  F
CTGGAGGTGGACGCTGACAACTGTGAGGAGGTGGTGAGAGAGTGC 1530
  L  E  V  D  A  D  N  C  E  E  V  V  R  E  C
GCCATCATGTGTGTCCCAACCTTTCAGTTTTATAAAAAAGAAGAA 1575
  A  I  M  C  V  P  T  F  Q  F  Y  K  K  E  E
AAGGTGGATGAACTTTGCGGCGCCCTTAAGGAAAAACTTGAAGCA 1620
  K  V  D  E  L  C  G  A  L  K  E  K  L  E  A
GTCATTGCAGAATTAAAGTAAACATGTATTCTGAAAAC  1658
  V  I  A  E  L  K ***
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